Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
China’s government has announced a series of measures to increase the country’s importation of drugs, including enhanced IP protection in the pharmaceutical industry.
China’s government has announced plans to implement preferential tax rates to generic drug makers in a bid to encourage the manufacturing of generics.
Japan-based Fujifilm has revealed its plan to acquire two cell culture media companies for $800 million.
Eisai has partnered with fellow Japanese pharmaceutical company Nichi-Iko Pharmaceutical to expand and grow Nichi-Iko’s generic business.
Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.
Japanese pharmaceutical company Eisai has teamed up with US-based Merck in a deal intended to strengthen the worldwide development and commercialisation of cancer drug Lenvima.
More than £500 million worth of life sciences and healthcare agreements were signed between the UK and China during the UK Prime Minister’s visit to China earlier this month.
Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
AstraZeneca has announced partnerships with Chinese companies Alibaba and Tencent, in agreements that will use emerging technologies to improve healthcare in China.